GLP-1 medications cost between roughly $900 and $1,350 per month at list price in the United States, depending on the specific drug and what it’s prescribed for. That’s the sticker price before insurance, coupons, or rebates, and what you actually pay can range from under $25 to the full amount depending on your coverage situation.
Monthly List Prices by Medication
The major GLP-1 medications cluster into two price tiers. Drugs approved for type 2 diabetes tend to cost slightly less than those approved specifically for weight loss, even when they contain the same active ingredient.
- Ozempic (semaglutide injection, for diabetes): $936 per month
- Rybelsus (semaglutide pill, for diabetes): $936 per month
- Mounjaro (tirzepatide injection, for diabetes): $1,023 per month
- Wegovy (semaglutide injection, for weight loss): $1,349 per month
Zepbound, the weight-loss version of tirzepatide, falls in a similar range to Wegovy. These figures come from list price data tracked by the Peterson-KFF Health System Tracker. Notably, the list price stays the same regardless of your dose level. Whether you’re on a low starter dose or the highest maintenance dose, you pay the same monthly amount for a given drug.
At full price, a year of treatment runs between $11,000 and $16,000. Since most people need to stay on these medications long-term to maintain results, the cumulative cost is a major factor in treatment decisions.
What You Actually Pay With Insurance
If you have commercial insurance that covers a GLP-1, your out-of-pocket cost drops significantly. Copays for preferred formulary drugs typically range from $25 to $150 per month, though this varies widely by plan. The catch is whether your plan covers the drug at all, and for which condition.
Coverage for diabetes is far more common than coverage for weight loss. Most commercial plans will cover Ozempic or Mounjaro when prescribed for type 2 diabetes with little pushback. Weight-loss coverage is a different story. Only 19% of large employers (those with 200 or more workers) cover GLP-1 drugs for weight loss in their largest health plan as of 2025. Larger companies are more generous: 43% of firms with 5,000 or more employees cover weight-loss use, compared to just 16% of firms with 200 to 999 employees.
Even when a plan technically covers these drugs, prior authorization is almost always required. Your doctor will need to document your BMI, any related health conditions, and sometimes evidence that you’ve tried other weight-loss approaches first. Denials are common, and appeals can take weeks.
Medicare Coverage Is Limited but Expanding
Medicare has historically not covered any medications prescribed purely for weight loss. That’s beginning to change, but slowly. Medicare Part D does cover GLP-1s prescribed for diabetes, and it now covers Wegovy for people with established cardiovascular disease and obesity or overweight, since the drug gained an FDA-approved heart-related indication. Zepbound is also covered when prescribed for obstructive sleep apnea in adults with obesity.
For broader weight-loss coverage, CMS announced a program called the Medicare GLP-1 Bridge, set to begin in July 2026. This short-term demonstration will cover certain GLP-1 drugs for weight reduction through December 2027, serving as a bridge to a longer-term model. To qualify, beneficiaries will need a BMI of 35 or higher, or a BMI of 30 or higher combined with specific conditions like uncontrolled hypertension, heart failure, or chronic kidney disease. The eligible drugs under this program include Wegovy, Zepbound, and Foundayo.
If you’re on Medicare today and want a GLP-1 for weight loss alone, you’re largely paying out of pocket unless your situation qualifies under one of the existing clinical indications.
Savings Programs and Discount Options
Both Novo Nordisk (maker of Wegovy and Ozempic) and Eli Lilly (maker of Mounjaro and Zepbound) offer savings card programs for commercially insured patients. These cards can reduce copays substantially, sometimes to $25 per month, though they come with monthly and annual spending caps. You’re not eligible if you’re on a government insurance plan like Medicare, Medicaid, or Tricare.
For people paying entirely out of pocket, Eli Lilly has offered cash-pay savings programs for Zepbound that bring the cost well below list price. These programs require a valid prescription but operate outside of insurance entirely. Availability and pricing for cash-pay programs shift frequently, so checking the manufacturer’s website directly gives you the most current numbers.
Compounding pharmacies have been another lower-cost option. During the semaglutide and tirzepatide shortages, the FDA allowed compounding pharmacies to produce custom versions of these drugs at significantly lower prices, sometimes $200 to $400 per month. As shortages resolve, the legal status of compounded versions becomes less certain, and quality can vary between pharmacies.
The First Generic GLP-1
In December 2024, the FDA approved the first generic GLP-1 medication: a generic version of Victoza (liraglutide), manufactured by Hikma Pharmaceuticals. Liraglutide is an older, once-daily injection primarily used for type 2 diabetes. It’s less potent for weight loss than the newer weekly injections like semaglutide and tirzepatide, but a generic version could offer a more affordable entry point for some patients.
Generic versions of the blockbuster drugs, Ozempic, Wegovy, Mounjaro, and Zepbound, remain years away. These medications are protected by extensive patent portfolios, and the injectable delivery systems add manufacturing complexity that slows generic development. For now, brand-name pricing dominates the market for the most effective GLP-1 options.
Why the U.S. Pays More
GLP-1 prices in the United States are dramatically higher than in other wealthy countries. The same medications cost a fraction of the U.S. price in countries where governments negotiate drug prices directly with manufacturers. The Peterson-KFF Health System Tracker has documented these gaps across peer nations. In the U.S., list prices don’t reflect the rebates manufacturers pay to insurers and pharmacy benefit managers, which means the “real” price in the system is lower than $936 or $1,349. But those hidden discounts don’t always reach patients, especially those without insurance or with high-deductible plans.
For someone paying cash at a U.S. pharmacy without any discount program, the register price will be at or near the full list price. That reality makes manufacturer savings programs, employer coverage decisions, and the eventual arrival of generics the key variables in what these drugs actually cost you.